Publication: New Article published in Breast Cancer Research

Thomas R. Cox, Aug 2013

Our recent article on the role of Lysyl Oxidase-like 2 (LOXL2) in breast cancer invasion and metastasis has just been published in Breast Cancer Research.

BCR_MCF10A

Image: Overexpressing the LOXL-2 protein (10A L2) fails to affect MCF10A breast cancer cells compared to control (10A cont)

In this paper we show that LOXL2 expression in normal epithelial cells of the breast can induce abnormal changes that resemble oncogenic transformation and cancer progression. We provide evidence to support that these effects are driven by LOXL2-mediated activation of ErbB2 and as such believe that LOXL2 may also be a potential biomarker for breast cancer patients that could benefit from anti-ErbB2 therapies.

Abstract

INTRODUCTION: Lysyl oxidase-like 2 (LOXL2) is a matrix-remodeling enzyme that has been shown to play a key role in invasion and metastasis of breast carcinoma cells. However, very little is known about its role in normal tissue homeostasis. Here, we investigated the effects of LOXL2 expression in normal mammary epithelial cells to gain insight into how LOXL2 mediates cancer progression. METHODS: LOXL2 was expressed in MCF10A normal human mammary epithelial cells. The 3D acinar morphogenesis of these cells was assessed, as well as the ability of the cells to form branching structures on extracellular matrix (ECM)-coated surfaces. Transwell-invasion assays were used to assess the invasive properties of the cells. Clinically relevant inhibitors of ErbB2, lapatinib and Herceptin (traztuzumab), were used to investigate the role of ErbB2 signaling in this model. A retrospective study on a previously published breast cancer patient dataset was carried out by using Disease Specific Genomic Analysis (DSGA) to investigate the correlation of LOXL2 mRNA expression level with metastasis and survival of ErbB2-positive breast cancer patients. RESULTS: Fluorescence staining of the acini revealed increased proliferation, decreased apoptosis, and disrupted polarity, leading to abnormal lumen formation in response to LOXL2 expression in MCF10A cells. When plated onto ECM, the LOXL2-expressing cells formed branching structures and displayed increased invasion. We noted that LOXL2 induced ErbB2 activation through reactive oxygen species (ROS) production, and ErbB2 inhibition by using Herceptin or lapatinib abrogated the effects of LOXL2 on MCF10A cells. Finally, we found LOXL2 expression to be correlated with decreased overall survival and metastasis-free survival in breast cancer patients with ErbB2-positive tumors. CONCLUSIONS: These findings suggest that LOXL2 expression in normal epithelial cells can induce abnormal changes that resemble oncogenic transformation and cancer progression, and that these effects are driven by LOXL2-mediated activation of ErbB2. LOXL2 may also be a beneficial marker for breast cancer patients that could benefit most from anti-ErbB2 therapy.

Links

View article on Breast Cancer Research homepage
View abstract on PubMed

Citation

Chang J, Nicolau MM, Wetterskog D, Cox TR, Barker HE, Erler JT. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
Breast Cancer Research 15:R67 (2013) | doi:10.1186/bcr3461

Funding

This work was supported by funding from the Breast Cancer Campaign, the Institute of Cancer Research (ICR), Cancer Research UK, AICR, the Biotech Research & Innovation Centre (BRIC) at the University of Copenhagen (UCPH) and a Hallas Møller Stipendum from the Novo Nordisk Foundation.